Floatz logo

hrs9531

Overweight or Obesity; Type 2 Diabetes

Fujian Shengdi Pharmaceutical Co., Ltd.Phase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Overweight or Obesity; Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Tirzepatide
Huazhong University of Science and Technology
Phase 4BB

Same molecule, other indications

hrs9531 is also rated in:

obesity disorderDormant
BB
Indicative ·
68 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
53 / 100
View asset →
diastolic heart failureDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →